Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.60 |
| ▸ | CDK2 | P24941 | 10/20 | 0.60 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.60 |
| ▸ | CDK4 | P11802 | 5/20 | 0.59 |
| ▸ | CCND3 | P30281 | 5/20 | 0.59 |
| ▸ | GSK3B | P49841 | 5/20 | 0.59 |
| ▸ | PIM1 | P11309 | 4/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 3/20 | 0.55 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.55 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | CCNK | O75909 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3205555 | 0.99 | CCNA2 (0.59) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3201117 | 0.95 | CCNA2 (0.55) | CCNA2CDK2CCNA1CDK4CCND3 | |
| Sulfuric Acid SCHEMBL3208098 | 0.95 | CCNA2 (0.55) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3210167 | 0.92 | CCNA2 (0.55) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3203546 | 0.89 | PAK1 (0.66) | JAK2JAK3TNIKPAK1 | |
| Hydrochloric Acid SCHEMBL3209167 | 0.88 | PAK1 (0.65) | JAK2JAK3TNIKPAK1 | |
| SCHEMBL13485402 | 0.88 | JAK2 (0.73) | JAK2JAK3TNIKPAK1 | |
| SCHEMBL14079526 | 0.86 | TNIK (0.51) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL3210121 | 0.85 | JAK2 (0.71) | JAK2JAK3TNIKPAK1 | |
| SCHEMBL3210186 | 0.85 | PAK1 (0.61) | JAK2JAK3TNIKPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | TOLERO PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011349-A2 | PYRIMIDINE-2,4-DIAMINE JAK2 KINASE INHIBITING ANTI-INFLAMMATION USE | SUPERGEN, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| WO-2008106635-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029675-A1 | Pyrimidine-2, 4-diamine JAK2 Kinase inhibiting anti-inflammation use | JAK2, JAK1, IRAK4 | CCNA2 876/4885CDK2 16/4885CCNA1 1698/4885 |
| US-20080214558-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVES AND THEIR USE AS JAK2 KINASE INHIBITORS | JAK2, JAK1, JAK3 | CCNA2 483/4885CDK2 6/4885CCNA1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.